Johnson & Johnson
JNJToday
+1.43%
5 Days
+4.97%
1 Month
+5.98%
6 Months
+18.03%
Year to Date
+30.44%
1 Year
+17.53%
TradingKey Stock Score of Johnson & Johnson
Currency: USD Updated: 2025-10-03Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Johnson & Johnson's Score
Support & Resistance
Score Analysis
Analyst Rating
Johnson & Johnson Highlights
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
News
Trump Plans Major Drug Price Cuts, Pharma Stocks Tumbles
Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.
.jpg)
Over 60,000 claims filed! Can Johnson & Johnson escape? The judge's stance is unwavering!
Johnson & Johnson (JNJ) is trying to handle claims through a bankruptcy plan. But the judge rejected it. The stock price may continue to decline.
US judge rejects J&J's $10 billion baby powder settlement
NEW YORK, March 31 (Reuters) - A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's JNJ.N $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.
What Are Defensive Stocks? Should You Buy Them Now? Are Defense Stocks Defensive?
TradingKey - Defensive stocks are seen as "safe havens" during economic downturns because their products or services maintain stable demand regardless of economic cycles. Warren Buffett’s investment success is largely attributed to his preference for defensive blue-chip stocks.
Worried About a Recession? 1 Healthcare Dividend Stock That Has Thrived In Every Market Crash
TradingKey - One of those sectors is healthcare and one of the biggest healthcare companies around is Johnson & Johnson (NYSE: JNJ), a company that also pays a decent dividend to shareholders.
Johnson & Johnson Medtech Shockwave Medical Announces U.S. Launch Of Shockwave Javelin Peripheral IVL Catheter
March 4 (Reuters) - Johnson & Johnson JNJ.N:JOHNSON & JOHNSON MEDTECH: SHOCKWAVE MEDICAL ANNOUNCES U.S. LAUNCH OF SHOCKWAVE JAVELIN PERIPHERAL IVL CATHETER
Financial Indicators
EPS
Total revenue
Johnson & Johnson Info
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
Related Instruments
Popular Symbols
